NASDAQ:PATH - UiPath Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $76.89
  • Forecasted Upside: 11.36 %
  • Number of Analysts: 19
  • Breakdown:
  • 0 Sell Ratings
  • 11 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.2 (-0.29%)

This chart shows the closing price for PATH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New UiPath Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PATH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PATH

Analyst Price Target is $76.89
▲ +11.36% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for UiPath in the last 3 months. The average price target is $76.89, with a high forecast of $86.00 and a low forecast of $64.00. The average price target represents a 11.36% upside from the last price of $69.05.

This chart shows the closing price for PATH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 19 polled investment analysts is to hold stock in UiPath.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/10/2021Evercore ISIReiterated RatingHold$72.00High
6/9/2021BMO Capital MarketsBoost Price TargetMarket Perform$80.00 ➝ $85.00High
6/9/2021Truist SecuritiesBoost Price TargetBuy$80.00 ➝ $82.00Medium
6/9/2021TruistBoost Price TargetBuy$80.00 ➝ $82.00High
6/9/2021Canaccord GenuityReiterated RatingHold$70.00 ➝ $75.00Medium
6/9/2021KeyCorpBoost Price TargetOverweight$82.00 ➝ $86.00High
6/9/2021Morgan StanleyBoost Price TargetEqual Weight$70.00 ➝ $72.00High
6/9/2021Needham & Company LLCReiterated RatingBuy$85.00High
6/9/2021BarclaysBoost Price TargetEqual Weight$71.00 ➝ $73.00High
5/24/2021OppenheimerInitiated CoverageMarket PerformHigh
5/19/2021Berenberg BankInitiated CoverageHold$64.00Low
5/17/2021Truist SecuritiesInitiated CoverageBuy$80.00N/A
5/17/2021MacquarieInitiated CoverageNeutral$69.00N/A
5/17/2021Wolfe ResearchInitiated CoveragePeer Perform$70.00N/A
5/17/2021DA DavidsonInitiated CoverageBuy$85.00N/A
5/17/2021Canaccord GenuityInitiated CoverageHold$70.00N/A
5/17/2021TruistInitiated CoverageBuy$80.00N/A
5/17/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$75.00N/A
5/17/2021MizuhoInitiated CoverageBuy$77.00N/A
5/17/2021Needham & Company LLCInitiated CoverageBuy$85.00N/A
5/17/2021CowenInitiated CoverageOutperform$82.00N/A
5/17/2021Morgan StanleyInitiated CoverageEqual Weight$70.00N/A
5/17/2021Royal Bank of CanadaInitiated CoverageSector Perform$74.00N/A
5/17/2021Bank of AmericaInitiated CoverageBuy$85.00N/A
5/17/2021JPMorgan Chase & Co.Initiated CoverageNeutral$68.00N/A
5/17/2021BMO Capital MarketsInitiated CoverageMarket Perform$80.00N/A
5/17/2021BarclaysInitiated CoverageEqual Weight$71.00N/A
5/17/2021KeyCorpInitiated CoverageOverweight$82.00N/A
5/17/2021Evercore ISIInitiated CoverageIn-Line$72.00N/A
5/17/2021OppenheimerReiterated RatingMarket PerformN/A
5/13/2021Berenberg BankInitiated CoverageHold$64.00N/A
(Data available from 6/24/2016 forward)
UiPath logo
UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. It develops UiPath Studio, a platform designed for RPA developers looking to build complex process automations with built-in governance capabilities, such as robust debugging tools, application programming interface automation, wizards to automate desktop or web applications, leverage custom code, and to integrate machine learning models into production workflows. The company also offers UiPath Robots, which emulates human behavior to execute the processes built in UiPath Studio; and UiPath Orchestrator that tracks and logs robot activity, along with what people do in tandem to maintain strict compliance and governance through dashboards and visualization tools. In addition, it provides maintenance and support for its software, as well as professional services, such as training and implementation services to facilitate the adoption of its platform. UiPath Inc. was founded in 2005 and is headquartered in New York, New York.
Read More

Today's Range

Now: $69.05
Low: $68.07
High: $69.85

50 Day Range

MA: $65.08
Low: $18.00
High: $85.12

52 Week Range

Now: $69.05
Low: $61.50
High: $90.00


2,189,935 shs

Average Volume

3,058,979 shs

Market Capitalization

$35.13 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of UiPath?

The following Wall Street sell-side analysts have issued research reports on UiPath in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Canaccord Genuity, Cowen Inc, DA Davidson, Evercore ISI, JPMorgan Chase & Co., KeyCorp, Macquarie, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, Truist, Truist Securities, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for PATH.

What is the current price target for UiPath?

19 Wall Street analysts have set twelve-month price targets for UiPath in the last year. Their average twelve-month price target is $76.89, suggesting a possible upside of 11.0%. KeyCorp has the highest price target set, predicting PATH will reach $86.00 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of $64.00 for UiPath in the next year.
View the latest price targets for PATH.

What is the current consensus analyst rating for UiPath?

UiPath currently has 11 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PATH, but not buy more shares or sell existing shares.
View the latest ratings for PATH.

What other companies compete with UiPath?

How do I contact UiPath's investor relations team?

UiPath's physical mailing address is 7 Great Valley Pkwy Ste 300, MALVERN, PA 19355-1425, United States. The healthcare company's listed phone number is +1-610-2320800 and its investor relations email address is [email protected] The official website for UiPath is